JLK-Ajou University, Cancer Diagnosis AI '99% Accuracy' Paper Published

JLK, the first medical AI company to be listed (CEO Dongmin Kim), announced on the 26th that a paper verifying the clinical effectiveness of the 'real-time AI cancer diagnosis solution,' jointly researched with the research team of Ajou University School of Medicine, was published in a world-renowned medical academic journal, recognizing its technological innovation and scientific significance.

The paper studied AI histopathology using confocal laser endomicroscopy (Artificial intelligence-based real-time histopathology of gastric cancer using confocal laser endomicroscopy) and was published in Precision Oncology, a Nature Partner Journals with a high impact factor.

According to the paper, JLK's AI solution, which analyzed biopsy specimens obtained through Endoscopic Submucosal Dissection (ESD) procedures in real time, recorded an accuracy of 99%, quickly and accurately diagnosing whether the patient had cancer. It also succeeded in classifying the type of cancer, distinguishing whether the cancer originated from epithelial cells or was another type.

Based on these experimental results, the research team predicted that the diagnostic time, which was previously analyzed through pathology after surgical specimen resection in the operating room, would be significantly shortened by artificial intelligence. Applying the AI solution allows real-time analysis of malignancy at the ESD procedure site simultaneously with specimen collection. In particular, it is expected to greatly assist medical staff in confirming clear resection margins during ESD procedures, where precise resection is crucial.

Dongmin Kim, CEO of JLK, said, "This research result will be a good example of how artificial intelligence technology can bring innovation to the medical field," adding, "We expect it to greatly contribute to changing the paradigm of cancer treatment and further improving patient survival rates. We will ensure that medical AI is widely utilized by integrating it with recently FDA-approved prostate cancer diagnostic solutions and more."

This content was produced with the assistance of AI translation services.